BridgeBio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on March 16, 2024, the compensation committee of BridgeBio's board of directors approved equity grants to 16 new employees in restricted stock units for an aggregate of 71,146 shares of the Company's common stock, with the effective date of March 18, 2024. One-fourth of the shares underlying each employee's restricted stock units will vest on February 16, 2025, with one-twelfth of the remaining shares underlying each such employee's restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee's continued employment with the Company or one of its subsidiaries on such vesting dates. All of the above-described awards were made under BridgeBio's Amended and Restated 2019 Inducement Equity Plan (the "Plan").
加利福尼亞州帕洛阿爾託，2024 年 3 月 20 日（GLOBE NEWSWIRE）——專注於遺傳性疾病和癌症的商業階段生物製藥公司 BridgeBio Pharma, Inc.（納斯達克股票代碼：BBIO）（“BridgeBio” 或 “公司”）今天宣佈，BridgeBio 董事會薪酬委員會於 2024 年 3 月 16 日批准向 16 名新員工提供限制性股票單位的股權補助公司普通股共計71,146股，生效日期爲2024年3月18日。每位員工的限制性股票單位所依據的四分之一的股份將在2025年2月16日歸屬，此後每位員工的限制性股票單位的剩餘股份的十二分之一將按季度歸屬，前提是每位此類員工在該歸屬日期繼續在公司或其子公司工作。上述所有獎勵均根據BridgeBio的經修訂和重述的2019年激勵股權計劃（“計劃”）發放。
The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by BridgeBio's board of directors in November 2019, and amended and restated on February 10, 2023 and on December 13, 2023.
根據納斯達克上市規則5635（c）（4），上述每項獎勵都是作爲激勵材料發放的，是根據該計劃的條款發放的。該計劃於2019年11月由BridgeBio董事會通過，並於2023年2月10日和2023年12月13日進行了修訂和重申。
About BridgeBio Pharma, Inc.
關於 BridgeBio 製藥公司
BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBio's pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn and Twitter.
BridgeBio Contact:
布里奇生物聯繫人：
Vikram Bali
contact@bridgebio.com
(650)-789-8220
巴厘島維克拉姆
contact@bridgebio.com
(650) -789-8220